AHMUMTi004-1
The cell line is not validated yet.
AHMUi004-A
General
Cell Line |
|
| hPSCreg name | AHMUi004-A |
| Cite as: | AHMUi004-A (RRID:CVCL_C1SI) |
| Alternative name(s) |
AHMUMTi004-1
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 10th April 2023 |
| User feedback | |
Provider |
|
| Generator | dongmei ji (AHMU) |
| Owner | The First Affiliated Hospital of Anhui Medical University (AYFY) |
External Databases |
|
| Cellosaurus | CVCL_C1SI |
| Wikidata | Q114310542 |
| BioSamples | SAMEA112795990 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed. |
External Databases (Donor) |
|
| BioSamples | SAMEA112885459 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Alternatives to consent are available? | No |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | the Ethics Committee of the Anhui Medical University (Hefei, China; Approval No. 20190190). |
| Approval number | No.20190190 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Plasmid |
| Genes | |
| Is the used vector excisable? |
Unknown |
| Absence of reprogramming vector(s)? |
Unknown |
| Reprogramming vectors silenced? | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Medium |
Other medium:
Base medium: DMEM/F12
Main protein source: Knock-out serum replacement Serum concentration: 10 % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
|
| Marker | Present | Absent |
| mCpG | ||
| OCT4 | X |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
No
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.